BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/25/2024 10:27:34 AM | Browse: 45 | Download: 187
 |
Received |
|
2024-06-21 13:04 |
|
Peer-Review Started |
|
2024-06-21 13:04 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-08-28 01:50 |
|
Revised |
|
2024-09-10 12:11 |
|
Second Decision |
|
2024-09-24 02:41 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-09-24 07:30 |
|
Articles in Press |
|
2024-09-24 07:30 |
|
Publication Fee Transferred |
|
2024-09-29 01:12 |
|
Edit the Manuscript by Language Editor |
|
2024-10-07 11:19 |
|
Typeset the Manuscript |
|
2024-10-11 05:36 |
|
Publish the Manuscript Online |
|
2024-10-25 10:27 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Drug-eluting beads chemoembolization combined with programmed cell death 1 inhibitor and lenvatinib for large hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hui Yang, Guang-Ping Qiu, Jie Liu and Tie-Quan Yang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Tie-Quan Yang, BMed, Attending Doctor, Department of Interventional Therapy, Ningbo No. 2 Hospital, No. 41 Xibei Road, Ningbo 315000, Zhejiang Province, China. younghc5@163.com |
| Key Words |
Large hepatocellular carcinoma; Conventional transarterial chemoembolization; Drug-eluting beads transarterial chemoembolization; Programmed cell death 1 inhibitor; Lenvatinib |
| Core Tip |
A retrospective analysis encompassing 104 patients diagnosed with large hepatocellular carcinoma (≥ 5 cm), focused on comparing the efficacy and safety of two treatment modalities, which were the triple combination therapy drug-eluting beads transarterial chemoembolization (D-TACE), programmed cell death 1 inhibitor, and lenvatinib (D-TACE-P-L) and the triple therapy consisting of conventional TACE, programmed cell death protein 1 inhibitor, and lenvatinib. Progression-free survival, tumor response, and adverse events were compared between two groups, and the findings revealed that D-TACE-P-L demonstrated significantly superior median progression-free survival and objective response rate, while maintaining comparable toxicity profiles. Based on these outcomes, this study proposed that the D-TACE-P-L therapy served as a preferential treatment option for individuals suffering from large hepatocellular carcinoma. |
| Publish Date |
2024-10-25 10:27 |
| Citation |
<p>Yang H, Qiu GP, Liu J, Yang TQ. Drug-eluting beads chemoembolization combined with programmed cell death 1 inhibitor and lenvatinib for large hepatocellular carcinoma. <i>World J Gastrointest Oncol</i> 2024; 16(11): 4392-4401</p> |
| URL |
https://www.wjgnet.com/1948-5204/full/v16/i11/4392.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v16.i11.4392 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
